GSK plc, aka GlaxoSmithKline, is rated a Buy at or below $45 due to relative undervaluation and a balanced, diversified portfolio. GSK's recent CEO transition and solid Q2 earnings have improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback